Granted Patent
B2
US 12,606,571 · App. 18/630,760 · Granted Apr 21, 2026
Macrocyclic compounds and uses thereof
Inventors:
Jingrong Jean Cui (Princeton, NC); Evan W. Rogers (Princeton, NJ); Jane Ung (Princeton, NJ); Jeffrey Whitten (Princeton, NJ); Dayong Zhai (Princeton, NJ); Wei Deng (Princeton, NJ); Xin Zhang (Princeton, NJ); Zhongdong Huang (Princeton, NJ); Jing Liu (Princeton, NJ); Han Zhang (Princeton, NJ)
Assignee:
Turning Point Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Claims (10)
1 . A compound having the structure:
or a salt thereof.
2 . The compound of claim 1 , having the structure:
3 . A compound having the structure:
4 . A compound having the structure:
5 . The compound of claim 4 having the structure:
6 . The compound of claim 4 having the structure:
7 . The compound of claim 4 having the structure:
8 . The compound of claim 4 having the structure:
9 . The compound of claim 4 having the structure:
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2026
From: CUI, JINGRONG JEAN; ROGERS, EVAN W.; UNG, JANE; WHITTEN, JEFFREY; ZHAI, DAYONG; DENG, WEI; ZHANG, XIN; HUANG, ZHONGDONG; LIU, JING; ZHANG, HAN
To: TURNING POINT THERAPEUTICS, INC.
Reel/Frame 074071/0585 →
Continuity (5)
Continuation
16634289
Provisional Application
62700990
· Jul 20, 2018
Provisional Application
62538193
· Jul 28, 2017
References Cited (253)
US 5639778A
· Andersson et al.
· 1997
[cited by applicant]
US 5698578A
· Heath et al.
· 1997
[cited by applicant]
US 6727256B1
· Carter et al.
· 2004
[cited by applicant]
US 8497270B2
· Thuring et al.
· 2013
[cited by applicant]
US 8680111B2
· Bailey et al.
· 2014
[cited by applicant]
US 8815872B2
· Yu et al.
· 2014
[cited by applicant]
US 8933084B2
· Andrews et al.
· 2015
[cited by applicant]
US 9714258B2
· Cui et al.
· 2017
[cited by applicant]
US 20140107099A1
· Blaney et al.
· 2014
[cited by applicant]
US 20160339027A1
· Carter et al.
· 2016
[cited by applicant]
US 20180325901A1
· Cui et al.
· 2018
[cited by applicant]
CL 2012003227A1
· 2013
[cited by applicant]
CN 1292788A
· 2001
[cited by applicant]
CN 102971322A
· 2013
[cited by applicant]
CN 106170289A
· 2016
[cited by applicant]
EP 3658148A1
· 2020
[cited by applicant]
JP 2012502043A
· 2012
[cited by applicant]
JP 2017503867A
· 2017
[cited by applicant]
KR 1020160111395A
· 2016
[cited by applicant]
TW 201612183A
· 2016
[cited by applicant]
WO 9935146A1
· 1999
[cited by applicant]
WO 0216369A2
· 2002
[cited by applicant]
WO 0246197A1
· 2002
[cited by applicant]
WO 2010028116A1
· 2010
[cited by applicant]
WO 2010033941A1
· 2010
[cited by applicant]
WO 2010048314A1
· 2010
[cited by applicant]
WO 2010051549A1
· 2010
[cited by applicant]
WO 2011146336A1
· 2011
[cited by applicant]
WO 2012034091A1
· 2012
[cited by applicant]
WO 2012136859A1
· 2012
[cited by applicant]
WO 2013001310A1
· 2013
[cited by applicant]
WO 2013028465A1
· 2013
[cited by applicant]
WO 2013045653A1
· 2013
[cited by applicant]
WO 2013132376A1
· 2013
[cited by applicant]
WO 2013134219A1
· 2013
[cited by applicant]
WO 2013134228A1
· 2013
[cited by applicant]
WO 2013147711A1
· 2013
[cited by applicant]
WO WO2015073267A1
· 2015
[cited by examiner]
WO 2015112806A2
· 2015
[cited by applicant]
WO 2015112806A3
· 2015
[cited by applicant]
WO 2017004342A1
· 2017
[cited by applicant]
WO 2017007759A1
· 2017
[cited by applicant]
WO 2017015367A1
· 2017
[cited by applicant]
WO 2018022911A1
· 2018
[cited by applicant]
WO WO2018077246A1
· 2018
[cited by examiner]
WO 2018140554A1
· 2018
[cited by applicant]
WO 2019023417A1
· 2019
[cited by applicant]
WO 2019120267A1
· 2019
[cited by applicant]
WO 2019201282A1
· 2019
[cited by applicant]
Furman et al. (2014) “Ibrutinib Resistance in Chronic Lymphocytic Leukemia”, The New England Journal of Medicine, 370(24):2352-2354.
[cited by applicant]
Gainor et al. (2013) “Novel Targets in Non-small Cell Lung Cancer: ROS1 and RET Fusions”, Oncologist, 18(7):865-875.
[cited by applicant]
Gao et al. (Mar. 29, 2016) “JAK2 Inhibition Sensitizes Resistant EGFR-mutant Lung Adenocarcinoma to Tyrosine Kinase Inhibitors”, Science Signaling, 9(421): ra33(11 pages).
[cited by applicant]
Gargalionis et al. (Jun. 21, 2013) “The Molecular Rationale of Src Inhibition in Colorectal Carcinomas”, International Journal of Cancer, 134(9):2019-2029.
[cited by applicant]
Gherardi et al. (2012) “Targeting MET in Cancer: Rationale and Progress”, Nature Reviews Cancer, 12(2):89-103.
[cited by applicant]
Ghiso et al. (Aug. 2013) “Targeting MET: why, where and how?”, Current Opinion in Pharmacology, 13(4):511-518.
[cited by applicant]
Golubovskaya et al. (2014) “Targeting FAK in Human Cancer: From Finding to First Clinical Trials”, Frontiers in Bioscience (Landmark Ed), 19:687-706 (30 pages).
[cited by applicant]
Gottesman, Michael M. (2002) “Mechanisms of Cancer Drug Resistance”, Annual Review of Medicine, 53:615-627.
[cited by applicant]
Grande et al. (2011) “Targeting Oncogenic Alk: A Promising Strategy for Cancer Treatment”, Molecular Cancer Therapeutics, 10(4):569-579.
[cited by applicant]
Gridelli et al. (Mar. 2014) “ALK inhibitors in the treatment of advanced NSCLC”, Cancer Treatment Reviews, 40(2):300-306.
[cited by applicant]
Grieco et al. (1990) “PTC is a Novel Rearranged form of the ret Proto-Oncogene and is Frequently Detected In Vivo in Human Thyroid Papillary Carcinomas”, Cell, 60(4):557-563.
[cited by applicant]
Gu et al. (Jan. 2011) “Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma”, PLoS ONE, 6(1):e15640(9 pages).
[cited by applicant]
Gunderson et al. (Mar. 2016) “Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer”, Cancer Discovery, 6(3):270-285.
[cited by applicant]
Hackam et al. (2006) “Translation of Research Evidence From Animals to Humans”, JAMA, 296(14):1731-1732.
[cited by applicant]
Halland et al. (Jan. 10, 2014) “Small Macrocycles as Highly Active Integrin α2β1 Antagonists”, ACS Medicinal Chemistry Letters, 5(2):193-198.
[cited by applicant]
Hammerman et al. (2011) “Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer”, Cancer Discovery, 1(1):78-89 (12 pages).
[cited by applicant]
Harbinski et al. (2012) “Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth”, Cancer Discovery, 2(10):948-959.
[cited by applicant]
Heynen et al. (Dec. 15, 2014) “Resistance to Targeted Cancer Drugs through Hepatocyte Growth Factor Signaling”, Cell Cycle, 13(24):3808-3817.
[cited by applicant]
James et al. (2005) “A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythemia Vera”, Nature, 434(7037):1144-1148.
[cited by applicant]
Jiang et al. (Aug. 2016) “Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy”, Nature Medicine, 22(8):851-860.
[cited by applicant]
Johnson et al. (Jun. 12, 2014) “Discovery of (10R)-7-Amino-12-fluoro-2,10, 16-Irimethyl-15--0xo-10, 15, 16, 17-tetrahydro-2H-8,4- 6 methane )pyrazolo[4,3-h][2,5, 11 ]-benzoxadiazacycloletradecine-3-carbonilrile (PF-0646…
[cited by applicant]
Jordan, Craig V. (Mar. 2003) “Tamoxifen: A Most Unlikely Pioneering Medicine”, Nature Reviews Drug Discovery, 2(3):205-213.
[cited by applicant]
Katayama et al. (Feb. 2012) “Mechanisms of Acquired Crizotinib Resistance in ALK-rearranged Lung Cancers”, Science Translational Medicine, 4(120):25 Pages.
[cited by applicant]
Katayama, Ryohei, (Sep. 2017) “Therapeutic Strategies and Mechanisms of Drug Resistance in Anaplastic Lymphoma Kinase (ALK)-Rearranged Lung Cancer”, Pharmacology & Therapeutics, 177:37 pages.
[cited by applicant]
Kato et al. (Apr. 15, 2017) “RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients”, Clinical Cancer Research, 23(8):1988-1997.
[cited by applicant]
Kentsis et al. (2012) “Autocrine Activation of the MET Receptor Tyrosine Kinase in Acute Myeloid Leukemia”, Nature Medicine, 18(7):1118-1122.
[cited by applicant]
Kiselyov, Alexander S. (Apr. 2005) “Solid Support Synthesis of 15-Membered Macrocycles Containing a Serotonin Unit”, Tetrahedron Letters, 46(17):3007-3010.
[cited by applicant]
Ko et al. (Jan. 2017) “MET/HGF Pathway Activation as a Paradigm of Resistance to Targeted Therapies”, Annals of Translational Medicine, 5(1):4.
[cited by applicant]
Kralovics et al. (Apr. 2005) “A Gain-of-function Mutation of JAK2 in Myeloproliferative Disorders”, The New England Journal of Medicine, 352(17):1779-1790.
[cited by applicant]
Kwak et al. (2005) “Irreversible Inhibitors of The EGF Receptor May Circumvent Acquired Resistance to Gefitinib”, Proceedings of the National Academy of Sciences, 102(21):7665-7670.
[cited by applicant]
Lacronique et al. (1997) “A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia”, Science, 278(5341):1309-1312.
[cited by applicant]
Lafave et al. (2012) “JAK2 The Future: Therapeutic Strategies for JAK-Dependent Malignancies”, Trends in Pharmacological Sciences, 33(11):574-582.
[cited by applicant]
Levine et al. (Apr. 2005) “Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myeloid Metaplasia with Myelofibrosis”, Cancer Cell, 7(4):387-397.
[cited by applicant]
Lin et al. (Feb. 2017) “Targeting ALK: Precision Medicine Takes on Drug Resistance”, Cancer Discovery, 7(2):137-155.
[cited by applicant]
Liu et al. (Jul. 2004) “Antiproliferative Effects of Src Inhibition on Medullary Thyroid Cancer”, The Journal of Clinical Endocrinology & Metabolism, 89(7):3503-3509.
[cited by applicant]
Liu et al. (2012) “Deregulated MYC Expression Induces Dependence Upon AMPK-Related Kinase 5”, Nature, 483:608-612.
[cited by applicant]
Liu et al. (Sep. 27, 2015) “The Molecular Effect of Metastasis Suppressors on Src Signaling and Tumorigenesis: New Therapeutic Targets”, Oncotarget, 6(34):35522-35541.
[cited by applicant]
Loudon, Marc G. (2002) “Organic Chemistry”, Fourth Edition, New York: Oxford University Press, USA, 1084-1085.
[cited by applicant]
Loudon, Marc G. (2002) “Organic Chemistry”, Fourth Edition, Oxford University Press, USA, 360-361.
[cited by applicant]
Ma et al. (2008) “Expression and Mutational Analysis of MET in Human Solid Cancers”, Genes Chromosomes Cancer, 47(12):1025-1037.
[cited by applicant]
Manning et al. (Dec. 6, 2002) “The Protein Kinase Complement of the Human Genome”, Science, 298(5600):1912-1934.
[cited by applicant]
Maulik et al. (2002) “Role of the Hepatocyte Growth Factor Receptor, c-Met, in Oncogenesis and Potential for Therapeutic Inhibition”, Cytokine & Growth Factor Reviews, 13(1):41-59.
[cited by applicant]
McCarthy et al. (May 8, 2014) “Tropomyosin Receptor Kinase Inhibitors: A Patent Update 2009-2013”, Expert Opinion on Therapeutic Patents, 24(7):731-744.
[cited by applicant]
Miller et al. (2007) “Solvent Systems for Crystallization and Polymorph Selection”, Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics, 53-109.
[cited by applicant]
Mohamed et al. (2009) “Bruton's Tyrosine Kinase (Btk): Function, Regulation, and Transformation with Special Emphasis on the PH Domain”, Immunological Reviews, 228(1):58-73.
[cited by applicant]
Monti, Elena (2007) “Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors”, Cancer Drug Resistance, 241-260.
[cited by applicant]
Morgillo et al. (2016) “Mechanisms of Resistance to EGFR-Targeted Drugs: Lung Cancer”, ESMO Open, 1(3):e000060:9 pages.
[cited by applicant]
Morris et al. (1994) “Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin's Lymphoma”, Science, 263(5151):1281-1284.
[cited by applicant]
Mosse et al. (Oct. 16, 2008) “Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene”, Nature, 455(7215):930-935 (20 pages).
[cited by applicant]
Müller et al. (Nov. 11, 1993) “The Protein Tyrosine Kinase JAK1 Complements Defects in Interferon-alpha/beta and -gamma Signal Transduction”, Nature, 366(6451):129-135.
[cited by applicant]
Mulligan, Lois M. (2014) “RET Revisited: Expanding the Oncogenic Portfolio”, Nature Reviews Cancer, 14(3):173-186.
[cited by applicant]
Murray, Peter J. (2007) “The JAK-STAT Signaling Pathway: Input and Output Integration”, Journal of Immunology, 178(5):2623-2629.
[cited by applicant]
Nefedova et al. (Oct. 15, 2005) “Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/signal Transducers and Activato…
[cited by applicant]
Neubauer et al. (May 1998) “Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis”, Cell, 93(3):397-409.
[cited by applicant]
Nosaka et al. (Jan. 1, 1995) “Defective Lymphoid Development in Mice Lacking Jak3”, Biochemistry, Molecular Biology, and Biophysics (CBS), 270(5237):800-802.
[cited by applicant]
Okamoto et al. (May 2010) “Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition”, Molecular Cancer Therapeutics, 9(5):1188-1197.
[cited by applicant]
Ongusaha et al. (2003) “P53 Induction and Activation of DDR1 Kinase Counteract P53-Mediated Apoptosis and Influence P53 Regulation through a Positive Feedback Loop”, The EMBO Journal, 22(6):1289-1301.
[cited by applicant]
Otsuka et al. (Nov. 15. 1998) “c-Met Autocrine Activation Induces Development of Malignant Melanoma and Acquisition of the Metastatic Phenotype1”, Cancer Research, 58:5157-5167.
[cited by applicant]
Pachnis et al. (1993) “Expression of the c-ret Proto-oncogene during Mouse Embryogenesis”, Development, 119:1005-1017.
[cited by applicant]
Pachter et al. (Feb. 1, 1961) “The Chemistry of Hortiamine and 6-Methoxyrhetsinine 1”, Journal of the American Chemical Society, 83(3):635-642.
[cited by applicant]
Park et al. (2014) “CRIPTO1 Expression in EGFR-mutant NSCLC Elicits Intrinsic EGFR-inhibitor Resistance”, The Journal of Clinical Investigation, 124(7):3003-3015.
[cited by applicant]
Park et al. (Jun. 20, 1986) “Mechanism of Met Oncogene Activation”, Cell, 45(6):895-904.
[cited by applicant]
Parsons et al. (2004) “Src Family Kinases, Key Regulators of Signal Transduction”, Oncogene, 23:7906-7909.
[cited by applicant]
Pennacchietti et al. (Nov. 15, 2014) “Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs”, Cancer Research, 74(22):6598-6609.
[cited by applicant]
Pesu et al. (Jul. 2008) “Therapeutic Targeting of Janus Kinases”, Immunological Reviews, 223(1):132-142.
[cited by applicant]
Peterson et al. (2006) “Expanding the Scope of Crystal Form Evaluation in Pharmaceutical Science”, Journal of Pharmacy and Pharmaceutical Sciences, 9(3):317-326.
[cited by applicant]
Pierotti et al. (Jan. 2006) “Oncogenic Rearrangements of the NTRK1/NGF Receptor”, Cancer Letters, 232(1):90-98.
[cited by applicant]
Pilotto et al. (Jan. 2017) “MET Exon 14 Juxtamembrane Splicing Mutations: Clinical and Therapeutical Perspectives for Cancer Therapy”, Annals of Translational Medicine, 5(1):11 pages.
[cited by applicant]
Planken et al. (2017) “Discovery of N-((3 R ,4 R )-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H-pyrazol-4-yl)amino)-9-methyl-9 H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High…
[cited by applicant]
Politi et al. (2014) “Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer”, Clinical Cancer Research, 20(22):5576-5578.
[cited by applicant]
Pubchem (Oct. 26, 2006) “(E)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide”, CAS No. 848133-17-5, 2 pages.
[cited by applicant]
Pubchem (Apr. 20, 2015) “Mavelertinib”, CAS No. 1776112-90-3, 2 pages.
[cited by applicant]
Pulford et al. (2004) “The Emerging Normal and Disease-Related Roles of Anaplastic Lymphoma Kinase”, Cellular and Molecular Life Sciences CMLS, 61(23):2939-2953.
[cited by applicant]
Quintas-Cardama et al. (Feb. 2011) “Janus Kinase Inhibitors for the Treatment of Myeloproliferative Neoplasias and Beyond”, Nature Reviews Drug Discovery, 10(2):127-140.
[cited by applicant]
Quintas-Cardama et al. (2010) “Preclinical Characterization of the Selective JAK1/2 Inhibitor INCB018424: Therapeutic Implications for the Treatment of Myeloproliferative Neoplasms”, Blood, 115(15):3109-3117.
[cited by applicant]
Rahal (Apr. 18, 2016) “The Development of Potent and Selective RET Inhibitors”, Presentation at Annual AACR Meeting, 76(Suppl 14):14 pages.
[cited by applicant]
Ravi et al. (2011) “Treatment of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis”, Current Opinion in Oncology, 23(4):361-366.
[cited by applicant]
Reiter et al. (Apr. 1, 2005) “The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2”, Cancer Research, 65(7):2662-2667.
[cited by applicant]
Ries et al. (2014) “Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy”, Cancer Cell, 25(6):846-859.
[cited by applicant]
Rudd et al. (2014) “Mutational Analysis of the Tyrosine Kinome in Serous and Clear Cell Endometrial Cancer Uncovers Rare Somatic Mutations in TNK2 and DDR1”, BMC Cancer, 884(14):9 pages.
[cited by applicant]
Sancier et al. (Feb. 24, 2011) “Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells”, PLoS ONE, 6(2):e17237(10 pages).
[cited by applicant]
Sawyers, Charles (Nov. 18, 2004) “Targeted Cancer Therapy”, Nature, 432(7015):294-297.
[cited by applicant]
Schiller et al. (Jan. 10, 2002) “Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer”, The New England Journal of Medicine, 346(2):92-98.
[cited by applicant]
Schuchardt et al. (1994) “Defects in the Kidney and Enteric Nervous System of Mice Lacking the Tyrosine Kinase Receptor Ret”, Nature, 367:380-383.
[cited by applicant]
Schwarz et al. (2014) “LYN-activating Mutations Mediate Antiestrogen Resistance in Estrogen Receptor-positive Breast Cancer”, The Journal of Clinical Investigation, 124(12):5490-5502.
[cited by applicant]
Sen et al. (2010) “Distinct Interactions between SRC and MET in Mediating Resistance to SRC Inhibition in Head and Neck Cancer”, Clinical Cancer Research, 17:1-11.
[cited by applicant]
Serrels et al. (Sep. 24, 2015) “Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity”, Cell, 163(1):160-173.
[cited by applicant]
Shan et al. (Jul. 1997) “Prodrug Strategies Based on Intramolecular Cyclization Reactions”, Journal of Pharmaceutical Sciences, 86(7):765-767.
[cited by applicant]
Shaw et al. (Nov. 20, 2014) “Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer”, The New England Journal of Medicine, 371(21):1963-1971.
[cited by applicant]
Shi et al. (2014) “MiR-204 Inhibits Human NSCLC Metastasis Through Suppression of NUAK1”, British Journal of Cancer, 111(12):2316-2327.
[cited by applicant]
Smolen et al. (2006) “Amplification of MET may Identify a Subset of Cancers with Extreme Sensitivity to the Selective Tyrosine Kinase Inhibitor PHA-665752”, Proceedings of the National Academy of Sciences, 103(7):2316-2…
[cited by applicant]
Soda et al. (2007) “Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer”, Nature, 448(7153):561-566.
[cited by applicant]
Sonbol et al. (2013) “Comprehensive Review of JAK Inhibitors in Myeloproliferative Neoplasms”, Therapeutic Advances in Hematology, 4(1):15-35.
[cited by applicant]
Song et al. (2014) “Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells”, International Journal of Molecular Sciences, 15(4):5838-5851.
[cited by applicant]
Song et al. (Aug. 2017) “Dual Inhibition of MET and SRC Kinase Activity as a Combined Targeting Strategy for Colon Cancer”, Experimental and Therapeutic Medicine, 14(2):1357-1366.
[cited by applicant]
Stabile et al. (2012) “C-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating Met”, Clinical Cancer Research, 19:1-13.
[cited by applicant]
Stanley et al. (2017) “Synergistic Effects of Various Her Inhibitors in Combination with IGF-1R, C-MET and Src Targeting Agents in Breast Cancer Cell Lines”, Scientific Reports, 7(1):1-15.
[cited by applicant]
Stransky et al. (2014) “The Landscape of Kinase Fusions in Cancer”, Nature Communications, 4846(5):10 pages.
[cited by applicant]
Straussman (2012) “Tumour Micro-environment Elicits Innate Resistance to RAF Inhibitors through HGF Secretion”, Nature, 487(7408):500-504.
[cited by applicant]
Summy et al. (2003) “Src Family Kinases in Tumor Progression and Metastasis”, Cancer and Metastasis Reviews, 22(4):337-358.
[cited by applicant]
Takahashi et al. (Sep. 1, 1985) “Activation of a Novel Human Transforming Gene, ret, by DNA Rearrangement”, Cell, 42(2):581-588.
[cited by applicant]
Takeuchi et al. (Nov. 2012) “RET, ROS1 and ALK Fusions in Lung Cancer”, Nature Medicine, 18(3):378-381.
[cited by applicant]
Thiele et al. (Oct. 2009) “On Trk—The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology”, Clinical Cancer Research, 15(19):5962-5967.
[cited by applicant]
Tomasson et al. (2008) “Somatic Mutations and Germline Sequence Variants in the Expressed Tyrosine Kinase Genes of Patients with De Novo Acute Myeloid Leukemia”, Blood, 111(9):4797-4808.
[cited by applicant]
Toso et al. (Oct. 9, 2014) “Enhancing Chemotherapy Efficacy in Pten-deficient Prostate Tumors by Activating the Senescence-associated Antitumor Immunity”, Cell Reports, 9(1):75-89.
[cited by applicant]
Trusolino et al. (Dec. 2010) “MET Signalling: Principles and Functions in Development, Organ Regeneration and Cancer”, Nature Reviews Molecular Cell Biology, 11(12):834-848.
[cited by applicant]
Uguen et al. (Aug. 2016) “ROS1 Fusions in Cancer: A Review”, Future Oncology, 12(16):1911-1928.
[cited by applicant]
Vainchenker et al. (Aug. 2008) “JAKs in Pathology: Role of Janus Kinases in Hematopoietic Malignancies and Immunodeficiencies”, Seminars in Cell & Developmental Biology, 19(4):385-393.
[cited by applicant]
Vaishnavi et al. (2013) “Oncogenic and Drug-Sensitive NTRK1 Rearrangements in Lung Cancer”, Nature Medicine, 19(11):1469-1472.
[cited by applicant]
Vaishnavi et al. (2015) “TRKing Down an Old Oncogene in a New era of Targeted Therapy”, Cancer Discovery, 5(1):25-34.
[cited by applicant]
Vergani et al. (Dec. 2011) “Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032”, Neoplasia, 13(12):1132-1142.
[cited by applicant]
Verma et al. (Oct. 2011) “Targeting Axl and Mer Kinases in Cancer”, Molecular Cancer Therapeutics, 10(10):1763-1773.
[cited by applicant]
Verstovsek et al. (2012) “A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis”, The New England Journal of Medicine, 366(9):799-807.
[cited by applicant]
Vetrie et al. (1993) “The Gene Involved in X-Linked Agammaglobulinemia is a Member of the Src Family of Protein-Tyrosine Kinases”, Nature, 361:226-233.
[cited by applicant]
Voena et al. (Apr. 23, 2016) “Oncogenic ALK Regulates EMT in Non-Small Cell Lung Carcinoma through Repression of the Epithelial Splicing Regulatory Protein 1”, Oncotarget, 7(22):33316-33330.
[cited by applicant]
Wiesner et al. (Oct. 15, 2015) “Alternative Transcription Initiation Leads to Expression of a Novel ALK Isoform in Cancer”, Nature, 526(7573):453-457.
[cited by applicant]
Wilson et al. (Dec. 1, 2012) “Widespread Potential for Growth-Factor-Driven Resistance to Anticancer Kinase Inhibitors”, Nature, 487(7408):505-509.
[cited by applicant]
Wojcik et al. (2006) “A Novel Activating Function of c-Src and Stat3 on HGF Transcription in Mammary Carcinoma Cells”, Oncogene, 25(19):2773-2784.
[cited by applicant]
Woyach et al. (2014) “Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib”, The New England Journal of Medicine, 370(24):2286-2294.
[cited by applicant]
Wrobel et al. (2004) “Autocrine CSF-1R Activation Promotes Src-dependent Disruption of Mammary Epithelial Architecture”, Journal of Cell Biology, 165(2):263-273.
[cited by applicant]
Xie et al. (Jan. 10, 2012) “Hepatocyte Growth Factor (HGF) Autocrine Activation Predicts Sensitivity to MET Inhibition in Glioblastoma”, Proceedings of the National Academy of Sciences, 109(2):570-575.
[cited by applicant]
Xu et al. (Apr. 25, 2016) “ARK5 Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Epithelial-mesenchymal Transition”, Cancer Letters, 377(2):140-148.
[cited by applicant]
Yang et al. (Feb. 28, 2017) “Tumor-Associated Macrophages: From Basic Research to Clinical Application”, Journal of Hematology & Oncology, 10(58):12 Pages.
[cited by applicant]
Yano et al. (2008) “Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-activating Mutations”, Cancer Research, 68(22):9479-9487.
[cited by applicant]
Yu et al. (2010) “An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression”, Cancer Cell, 17(5):443-454.
[cited by applicant]
Yu et al. (Apr. 15, 2013) “Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers”, Clinical Cancer Research, 19(8):2240-2247.
[cited by applicant]
Yurovskaya et al. (Apr. 2011) “Some Aspects of the Relationship Between Chirality and Biological Activity”, Advances in Synthesis and Complexation. Materials of the All-Russian Scientific Conference, 19-20.
[cited by applicant]
Zardan et al. (2014) “Lyn Tyrosine Kinase Regulates Androgen Receptor Expression and Activity in Castrate-resistant Prostate Cancer”, Oncogenesis e115, 3:10 pages.
[cited by applicant]
Zhang et al. (Jul. 1, 2012) “Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer”, Nature Genetics, 44(8):852-860.
[cited by applicant]
Zhang et al. (2009) “Targeting Cancer with Small Molecule Kinase Inhibitors”, Nature Reviews Cancer, 9(1):28-39.
[cited by applicant]
Zhang et al. (2012) “Targeting Src Family Kinases in Anti-Cancer Therapies: Turning Promise into Triumph”, Trends in Pharmacological Sciences, 33(3):122-128 (14 pages).
[cited by applicant]
Zou et al. (2007) “An Orally Available Small-Molecule Inhibitor of C-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Anti Proliferative and Antiangiogenic Mechanisms”, Cancer Research, 67(9):4408-4417.
[cited by applicant]
Zou et al. (Mar. 17, 2015) “Pf-06463922 is a Potent and Selective Next-Generation Ros1/Alk Inhibitor Capable of Blocking Crizolinibesislanl Ros1 Mutations”, Proceedings of the National Academy of Sciences, 112(11):3493-…
[cited by applicant]
(Aug. 10, 2015) Pubchem SID 252159180, 4 pages.
[cited by applicant]
(Dec. 11, 2015) 1-(5-Methyl-1,6,7,8-tetrahydropyrrolo[2,3-g]quinolin-3-yl)ethanone, PubChem CID 98009788, 10 pages.
[cited by applicant]
Extended European Search Report issued in European Application No. 16828471.9, mailed on Mar. 26, 2019, 7 pages.
[cited by applicant]
Extended European Search Report issued in European Application No. 16818768.0, mailed on Jan. 30, 2019, 12 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US18/043817, mailed on Feb. 6, 2020, 9 pages.
[cited by applicant]
International Search Report and Written Opinion received for Application No. PCT/US2015/012597, mailed on Aug. 28, 2015, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for Application No. PCT/US2016/043132, mailed on Sep. 28, 2016, 15 pages.
[cited by applicant]
International Search Report and Written Opinion received for Application No. PCT/US2017/044214, mailed on Dec. 1, 2017, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US18/043817, mailed on Oct. 16, 2018, 16 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2016/040329, mailed on Sep. 7, 2016, 18 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT/US2016/040972, mailed on Sep. 13, 2016, 8 pages.
[cited by applicant]
(Nov. 25, 2017) PubChem-CID 34835133, PubChem, 6 pages.
[cited by applicant]
Advani et al. (Aug. 2002) “Bcr-Abl Variants: Biological and Clinical Aspects”, Leukemia Research, 26(8):713-720.
[cited by applicant]
Ambrogio et al. (Mar. 2016) “Combined Inhibition of DDR1 and Notch Signaling is a Therapeutic Strategy for KRAS-driven Lung Adenocarcinoma”, Nature Medicine, 22(3):270-277.
[cited by applicant]
Anastassiadis et al. (2011) “Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity”, Nature Biotechnology, 29(11):1039-1045 (19 pages).
[cited by applicant]
Apicella et al. (2017) “Dual MET/EGFR Therapy Leads to Complete Response and Resistance Prevention in a MET-Amplified Gastroesophageal Xenopatient Cohort”, Oncogene, 36:1200-1210.
[cited by applicant]
Arlauckas et al. (May 10, 2017) “In Vivo Imaging Reveals a Tumor-associated Macrophage-mediated Resistance Pathway in Anti-pd-1 Therapy”, Science Translational Medicine, 9(389):20 pages.
[cited by applicant]
Awad et al. (2013) “Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1”, The New England Journal of Medicine, 368(25):2396-2401.
[cited by applicant]
Bagshawe, Kenneth D. (Feb. 1995) “Antibody-Directed Enzyme Prodrug Therapy: A Review”, Drug Development Research, 34(2):220-230.
[cited by applicant]
Baldanzi et al. (Mar. 2015) “Physiological Signaling and Structure of the HGF Receptor MET”, Biomedicines, 3(1):1-31.
[cited by applicant]
Balko et al. (Apr. 13, 2016) “Triple Negative Breast Cancers with Amplification of JAK2 At The 9p24 Loci Demonstrate JAK2-Specific Dependence”, Science Translational Medicine, 8(334): 25 pages.
[cited by applicant]
Bardelli et al. (2013) “Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer”, Cancer Discovery, 3(6):658-673.
[cited by applicant]
Baxter et al. (2005) “Acquired Mutation of the Tyrosine Kinase JAK2 in Human Myeloproliferative Disorders”, Lancet, 365(9464):1054-1061.
[cited by applicant]
Bender et al. (Mar. 2016) “Btk Inhibition Treats TLR7/IFN Driven Murine Lupus”, Clinical Immunology, 164:65-77.
[cited by applicant]
Bender et al. (Nov. 2016) “Recurrent MET Fusion Genes Represent a Drug Target In Pediatric Glioblastoma”, Nature Medicine, 22:1314-1320.
[cited by applicant]
Berge et al. (Jan. 1977) “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 66(1):1-19.
[cited by applicant]
Berndt et al. (Aug. 2017) “Advances of Small Molecule Targeting of Kinases”, Current Opinion in Chemical Biology, 39:126-132 (12 pages).
[cited by applicant]
Bertolini et al. (Jun. 20, 1997) “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug”, Journal of Medicinal Chemistry, 40(13):2011-2016.
[cited by applicant]
Bertotti et al. (Aug. 2010) “Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors”, Clinical Cancer Research, 16(15):3933-3943.
[cited by applicant]
Bischof et al. (Apr. 1997) “Role of the Nucleophosmin (NPM) Portion of the Non-Hodgkin's Lymphoma-Associated NPM-Anaplastic Lymphoma Kinase Fusion Protein in Oncogenesis”, Molecular and Cellular Biology, 17(4):2312-2325.
[cited by applicant]
Blake et al. (2000) “SU6656, A Selective Src Family Kinase Inhibitor, Used to Probe Growth Factor Signaling”, Molecular and Cellular Biology, 20(23):9018-9027.
[cited by applicant]
Boccaccio et al. (Aug. 2006) “Invasive Growth: A MET-driven Genetic Programme for Cancer and Stem Cells”, Nature Reviews Cancer, 6(8):637-645.
[cited by applicant]
Bodor et al. (1984) “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems”, Advances in Drug Research, 13:255-331.
[cited by applicant]
Bottaro et al. (Feb. 15, 1991) “Identification of the Hepatocyte Growth Factor Receptor as the c-met ProtoOncogene Product”, Science, 251(4995):802-804.
[cited by applicant]
Bradley et al. (2017) “Targeting c-MET in Gastrointestinal Tumours: Rationale, Opportunities and Challenges”, Nature Reviews Clinical Oncology, 14(9):562-576.
[cited by applicant]
Bromann et al. (2004) “The Interplay between Src Family Kinases and Receptor Tyrosine Kinases”, Oncogene, 23(48):7957-7968.
[cited by applicant]
Buchert et al. (2016) “Targeting JAK Kinase in Solid Tumors: Emerging Opportunities and Challenges”, Oncogene, 35:939-951.
[cited by applicant]
Charest et al. (May 2003) “Fusion of FIG to the Receptor Tyrosine Kinase ROS in a Glioblastoma wth an Interstitial Del(6)(Q21q21)”, Genes Chromosomes Cancer, 37(1):58-71.
[cited by applicant]
Chiron et al. (2014) “Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma”, Cancer Discovery, 4 (9):1022-1035.
[cited by applicant]
Cooper et al. (1984) “Molecular Cloning of a New Transforming Gene from a Chemically Transformed Human Cell Line”, Nature, 311:29-33.
[cited by applicant]
Couronne et al. (Nov. 15, 2013) “Activating Mutations in fyn Kinase in Peripheral T-Cell Lymphomas”, Blood, 122(21):811(2 pages).
[cited by applicant]
Crystal et al. (2014) “Patient-Derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer”, Science, 346(6216):1480-1486.
[cited by applicant]
Cui et al. (Aug. 3, 2011) “Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)”,…
[cited by applicant]
Davies et al. (Aug. 1, 2013) “Molecular Pathways: ROS1 Fusion Proteins in Cancer”, Clinical Cancer Research, 19(15):4040-4045.
[cited by applicant]
Di Paolo et al. (Jan. 2011) “Specific Btk Inhibition Suppresses B Cell- and Myeloid Cell-mediated Arthritis”, Nature Chemical Biology, 7:41-50.
[cited by applicant]
Dimitroff et al. (1999) “Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy”, Investigational New Drugs, 17(…
[cited by applicant]
Dulak et al. (2011) “HGF-independent Potentiation of EGFR Action by c-Met”, Oncogene, 30(33):3625-3635.
[cited by applicant]
Elias et al. (2015) “Fyn is an Important Molecule in Cancer Pathogenesis and Drug Resistance”, Pharmacological Research, 100:250-254.
[cited by applicant]
Engelman et al. (May 18, 2007) “MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling”, Science, 316(5827):1039-1043.
[cited by applicant]
Fujita-Sato et al. (2015) “Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions”, Cancer Research, 75(14):2851-2862.
[cited by applicant]